ILF Webinar: Report back on PADO 3 review
5 February 2018

With the availability of new evidence, and progress in the development of new drugs (including paediatric formulations), the Paediatric ARV Drug Optimization (PADO) group recently reviewed its list of priority paediatric ARV formulations. The review focused on implementation, taking into consideration alignment with drug optimization efforts for adults through the Conference on Drug Optimization (CADO) 3 meeting, and in preparation for the upcoming WHO ART guidelines review (planned for Q2 2018).

In collaboration with the WHO and CHAI, the ILF hosted a webinar to report back on the PADO 3 review. This interactive session covered the latest discussions around the list of priority paediatric ARV formulations.

Watch the webinar recording

Webinar material

  • Related documents
  • Presentations
  • Multimedia

Welcome and introduction
Sébastien Morin (IAS)


PADO 3 Implementation: Progress and remaining hurdles in a changing environment
Martina Penazzato (WHO)


PADO 3 Implementation: Internal prioritization to maximize impact
Melynda Watkins (CHAI)


Remaining evidence gaps: the PADO research agenda
Marissa Vicari (IAS)


Webinar recording